CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Nurses' roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome.
Nurses' roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
讨论了护士对经历 CAR-T 毒性反应的患者的职责,特别关注治疗期间发生的 CRS。
近年来,癌症免疫治疗取得了显著创新。这些创新带来了积极成果,包括癌症患者临床结局的大幅改善,尤其是在涉及B细胞恶性肿瘤患者的B细胞环境中。
本文探讨肿瘤科护士在应用CAR-T 细胞疗法中的实际角色与扩展角色。
CAR-T 疗法是癌症治疗中一项令人振奋的创新。然而,这种疗法常伴随一些轻度至危及生命的副作用和毒性,包括细胞因子释放综合征(CRS)。遗憾的是,护士缺乏足够的标准化指南来监测和管理 CRS 患者。本文基于经验和已发表数据,阐述了肿瘤科护士在利用 CAR-T 疗法治疗 B 细胞恶性肿瘤中的实际作用和扩展作用。
INTRODUCTION: In recent times, significant innovations have been made in cancer immunotherapy. These innovations have yielded positive outcomes, including a substantial improvement in the clinical outcomes of cancer patients, especially in the B-cell setting involving patients with B-cell malignancies. METHOD: This paper explores oncology nurses' actual and expanded roles in utilizing chimeric antigen receptor T-cell (CAR-T) therapy. RESULT: CAR-T therapy is an exciting innovation in cancer treatment.
However, this therapy is often associated with some mild to life-threatening side effects and toxicities, including cytokine release syndrome (CRS). Unfortunately, nurses lack adequate standardized guidelines for monitoring and managing patients with CRS.
This paper explains oncology nurses' actual and expanded roles in utilizing CAR-T therapy in treating B-cell malignancies based on experience and published data. DISCUSSION: Nurses' responsibilities for patients experiencing CAR-T toxicities with a particular focus on CRS during treatment are discussed.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。